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Patients  with  lower-risk  myelodysplastic  syndromes  (MDS)  are affected  primarily  by  symptoms  of
chronic  anemia  and  fatigue  rather  than progression  to acute  myeloid  leukemia.  Severe  thrombocytope-
nia,  although  less  common  in  lower-risk  MDS,  is  associated  with  increased  risk  of bleeding.  For  anemic
patients,  the  principal  aim of  treatment  is  to improve  anemia  and  decrease  red  blood  cell  transfusions.
For  transfusion-dependent  patients  with  lower-risk  MDS  without  chromosome  5q  deletion  [non-del(5q)
MDS],  there  are  limited  effective  treatments.  Erythropoiesis-stimulating  agents  (ESAs)  are generally  ﬁrst-
line therapy,  yielding  frequent  responses  with  a median  duration  of 18–24  months.  Immunosuppressive
therapy or  allogeneic  stem  cell  transplantation  are  restricted  to select  patients.  New strategies  for  ESA-
refractory  or  relapsed  patients  include  lenalidomide,  alone  or  in  combination  with ESAs; oral  azacitidine;
and  new  molecules  such  as  the  activin  receptor  type  II ligand  traps  luspatercept  and  sotatercept.  In throm-reatment bocytopenic  patients,  thrombopoietin  receptor  agonists  are  under  evaluation.  While  trials  to  evaluate
these  treatment  strategies  are  underway,  efforts  are  needed  to optimize  therapies  through  better  patient
selection  and  response  prediction  as well  as integrating  molecular  and  genetic  data  into  clinical  practice.
We  provide  an  overview  of  current  treatment  approaches  for lower-risk  non-del(5q)  MDS  and  explore
promising  directions  for  future  research.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
.1. The burden of MDS
Myelodysplastic syndromes (MDS) are a group of malignant
one marrow disorders characterized by ineffective hematopoiesis
eading to refractory cytopenias, with an increased risk of progres-
ion to acute myeloid leukemia (AML) [1]. Development of MDS  is
 multifactorial process that includes mutations in genes affecting
arious cellular pathways [2,3]. Outcomes in this group of disor-
ers vary widely, and prognostic scoring systems were developed
o stratify patients into lower- and higher-risk groups based on
aboratory features [4,5]. The widely used International Prognostic
coring System (IPSS) stratiﬁes patients into 4 risk groups (Low,
ntermediate-1, Intermediate-2, and High) based upon the per-
entage of blasts in the bone marrow, karyotype, and number of
ytopenias present [4]. Further reﬁnements to risk-group deﬁni-
ions were made in the revised IPSS (IPSS-R) by assigning greater
eight to the cytogenetic risk categories and the severity of cytope-
ias, and by reﬁning bone marrow blast percentage thresholds [5].
urrent studies are integrating data on somatic gene mutations into
rognostic indices to further reﬁne risk stratiﬁcation [6–8].
MDS  represents one of the most common hematologic malig-
ancies in Western countries whose incidence markedly increases
ith age [9]. In patients aged ≥ 70 years in Western countries, the
ncidence of MDS  is conservatively estimated at 30–40 cases per
00,000 population per year [10,11]. With an aging population, an
scalation in the number of cases of MDS  is expected in the coming
ears. Notwithstanding the reduced rate of leukemic transforma-
ion of lower-risk patients, most patients are affected by anemia
nd anemia-related symptoms with profound effects on patient-
eported outcomes. In addition, patients may  have an increased
isk of hemorrhagic complications due to thrombocytopenia and
latelet dysfunction. In a study of patients with lower-risk MDS,
emoglobin level was the most important independent predictor
f health-related quality of life (HRQoL) [12]. In addition, ane-
ia  is associated with greater cardiovascular complications and
n increased risk of falls [13]. According to data from the European
eukemiaNet MDS  (EUMDS) registry, 51% (508 of 1000) of patients
ith lower-risk MDS  received red blood cell (RBC) transfusions
ithin 2 years of diagnosis, of whom 20% (197 of 1000 patients) had
eceived transfusions prior to the diagnosis of MDS  [14]. Chronic
ransfusions may  have a profound impact on patients’ everyday
ives. In a survey of transfusion-dependent (TD) MDS  patients, 34%
eported that they felt they were burdening their family, and 65%
aid they would consider treatment that temporarily made them
eel worse if it stopped or reduced the need for transfusions [13].
oreover, previous research has shown that TD MDS  patients typ-cally have signiﬁcantly lower overall survival (OS) than those who
o not require regular transfusions [15–17]. . . . . . . . . . . .  . . .  . . . . .  . . . . .  . . . . .  . . .  .  . . . .  . . .  . . .  . .  . .  .  . . . .  . . .  .  .  .  . . . .  .  . . . . .  . . . . .  . . . 55
Here, we  discuss current approaches to the management of
lower-risk MDS  without chromosome 5q deletion [non-del(5q)
MDS], highlighting the potential beneﬁt of therapies currently
under development. A detailed evaluation of the current literature,
which was  carried out in preparation for this review, is provided in
the Supporting information.
2. Current treatment approaches for lower-risk
non-del(5q) MDS
2.1. MDS treatment guidelines
Improving anemia and anemia-related symptoms while reduc-
ing transfusion burden are the therapeutic goals in patients
with TD lower-risk MDS. Current guidelines developed by the
National Comprehensive Cancer Network [18], European Leukemi-
aNet (ELN) [19], and European Society for Medical Oncology (ESMO)
[20] are generally consistent with regard to the management of
patients with lower-risk non-del(5q) MDS. Pre-emptive treatment
of asymptomatic patients is not recommended, and treatment
should be reserved for those with symptomatic cytopenias, in par-
ticular anemia. Initial treatment decisions are based on serum
erythropoietin (EPO) level and RBC transfusion requirement. For
younger patients, the likelihood of response to immunosuppressive
therapy (IST) is also considered [18,19].
3. Treatment of anemia
3.1. RBC transfusion
RBC transfusion remains a key component of supportive care
and symptom management for all MDS  patients. Approaches
vary between countries and individual treatment centres; how-
ever, in general, RBC transfusions are recommended for patients
with severe anemia (hemoglobin < 8 g/dl) or symptomatic anemia
(regardless of hemoglobin level) [18,19].
Although RBC transfusions are essential for short-term symp-
tom management, RBC transfusion dependence (RBC-TD) and its
intensity may  be a marker of more aggressive disease and deﬁne
a group of patients with poor prognosis [19]. In fact, RBC-TD is
associated with various complications in lower-risk MDS  patients,
including increased hospitalizations, iron overload, and higher
morbidity, due to ﬂuctuations in hemoglobin levels, which may
result in shorter OS. Data from a retrospective analysis of 467 MDS
patients showed that RBC-TD was associated with both inferior OS
(P < 0.001) and shorter leukemia-free survival (P < 0.001) [15]. In a
similar study of 381 untreated patients with lower-risk MDS  and
del(5q), RBC-TD patients had signiﬁcantly shorter OS (44 months)
compared with transfusion-independent (TI) patients (97 months;
P < 0.0001) [17]. Although the economic impact of RBC transfusions
is not comparable with that of active treatment, it is not negligible
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nd should be taken into account when evaluating the costs and
ealth beneﬁts of treatment [21].
.2. Erythropoiesis-stimulating agents (ESAs)
ESAs are generally accepted as the ﬁrst-line treatment for symp-
omatic anemia for most patients with lower-risk non-del(5q) MDS.
he beneﬁts of recombinant human EPO (rhEPO) have been eval-
ated in several studies [22–28]. Treatment with rhEPO should be
onsidered for lower-risk patients with low transfusion burden (<2
acked RBC units per month) or low baseline serum EPO levels
<500 mU/ml) [19] as these factors have consistently been shown to
redict response to ESAs [22,24,29,30]. Increased access to medical
are and increased awareness of the disease have led to earlier diag-
osis of lower-risk MDS  patients [30]. Consequently, the majority of
ewly diagnosed lower-risk MDS  patients with symptomatic ane-
ia  have baseline serum EPO levels <500 mU/ml  and either no or a
elatively low RBC transfusion requirement and, therefore, would
e eligible for a therapeutic trial with ESAs [31].
Other parameters predictive of response to ESAs in MDS  patients
nclude normal cytogenetics, low blast percentage (<10%) in the
one marrow, and World Health Organization (WHO) subtypes RA
refractory anemia) and RARS (RA with ring sideroblasts) [32]. In
 recent retrospective analysis of IPSS lower-risk patients previ-
usly selected for treatment with ESAs on the basis of the above
eported criteria (i.e., low serum EPO and transfusion requirement),
hose who were classiﬁed as High and Very High risk according to
he IPSS-R had lower response rates to ESAs [33]. In multivariate
nalysis, IPSS-R score, serum EPO, and serum ferritin level were sig-
iﬁcantly associated with erythroid response (from 85% response
n IPSS-R Very Low-risk patients to 31% in Very High-risk patients).
 model based on IPSS-R score, serum EPO, and serum ferritin level
ay  provide additional value in predicting the response to ESAs
33]. In a recent study by Kosmider et al., there was an inverse
orrelation between the number of somatic gene mutations and
esponse to ESAs [34]. These data suggested that early initiation of
SA therapy may  increase the likelihood of a long-term response
34].
ESAs and granulocyte colony-stimulating factor (G-CSF) are
elieved to act synergistically to promote production of erythro-
ytes and inhibit apoptosis. Several studies have suggested that
atients with ring sideroblasts are more likely to respond to the
ombination of ESAs and G-CSF than to ESAs alone [35,36]; these
ata, however, are disputed by others [37]. There are no data
rom randomized prospective studies to conﬁrm this [38]. With
he introduction of higher-dose ESA therapy, including long-acting
orms, G-CSF combination therapy may  offer less beneﬁt over what
an be achieved by ESAs alone (unpublished data from French MDS
tudy group; [39]).
Data from both retrospective and prospective studies indicate
hat response to growth factors is associated with improved quality
f life [26,28,30,40–44]. These studies further suggest that response
o ESAs does not increase the risk of AML  progression, but instead
onfers a possible survival beneﬁt [41,42]. This may  be due to
mproved hemoglobin levels, fewer cardiovascular complications,
nd/or reductions in iron overload in responding patients com-
ared with those who require regular transfusions, as well as more
avorable disease biology as reﬂected by the higher probability of
esponse in those with the lowest IPSS-R score.
The cumulative data strongly support ESAs as effective ﬁrst-line
trategy for a majority of lower-risk MDS  patients who  have symp-
omatic anemia and baseline serum EPO <500 mU/ml. Although
here is insufﬁcient evidence to conclude that ESAs may  improve
S, these data highlight effectiveness of this therapy in reducing or
elaying onset of RBC-TD.search 52 (2017) 50–57
3.3. Iron chelation therapy (ICT)
An important side effect of chronic RBC transfusions is systemic
iron overload. Among patients with MDS, those with lower-risk dis-
ease are more likely to receive transfusions over an extended period
of time and, therefore, have a higher risk of iron overload, with up
to 60% of these patients reported to develop iron overload [45].
Sustained administration of ICT to these patients continues to be a
challenge. Both the ELN and NCCN guidelines recommend ICT for
patients receiving chronic RBC transfusions to minimize the con-
sequences of iron overload. Although the guidelines lack uniform
recommendations, most recommend initiating ICT in patients with
RBC-TD MDS  when serum ferritin levels reach 1000–2500 ng/ml
[18,19].
The beneﬁts of ICT in patients with thalassemia are well estab-
lished; however, randomized trials supporting the effectiveness of
ICT on clinical outcomes in MDS  patients are lacking [46–48]. In a
retrospective study, use of ICT was an independent covariate associ-
ated with improved OS in patients with lower-risk MDS  receiving
regular transfusions [49]. Given the difﬁculties in adequate par-
enteral chelation with desferrioxamine in the elderly population,
4 prospective Phase 2 studies evaluated the effect of the oral iron
chelator deferasirox in RBC-TD patients with lower-risk MDS. The
EPIC study included 341 patients with MDS  and showed a signiﬁ-
cant reduction in serum ferritin levels with deferasirox treatment
[47,50]. Similarly, in a US multicenter study involving 176 TD lower-
risk MDS  patients, median serum ferritin levels decreased by 23.2%
in patients who  completed 12 months of deferasirox treatment,
36.7% in patients who  completed 2 years, and 36.5% in patients who
completed 3 years despite continued transfusion requirements.
This reduction in ferritin levels was accompanied by normalization
of non-transferrin-bound serum iron [51]. Deferasirox signiﬁcantly
reduced liver iron concentrations in a study of 47 MDS  patients
by Porter et al. [46]. Among 159 patients with lower-risk MDS and
signs of iron overload, ICT was  shown to reduce serum ferritin level
[48].
There is increasing evidence to suggest that ICT can improve
hematopoiesis and lead to a reduction of RBC transfusion require-
ments in MDS  [52,53]. The exact mechanism by which this occurs
is not completely understood. Data from preclinical studies sug-
gest that buildup of reactive oxygen species generated by excess
iron may  compromise the clonogenic and differentiation potential
of hematopoietic stem and progenitor cells [54,55]. Iron overload-
induced oxidative stress may  also negatively affect hematopoiesis
by altering the supportive bone marrow stroma environment [56].
Deferasirox induced erythroid and platelet responses in 11% and
15% of patients, respectively; the 12-month cumulative incidence
of RBC transfusion independence (TI) adjusted for death and disease
progression was 15.5% [48].
The long-term beneﬁts of ICT in MDS  have yet to be demon-
strated prospectively in a randomized trial. Data from the
ongoing prospective TELESTO trial (ClinicalTrials.gov Identiﬁer:
NCT00940602) will hopefully provide insight into the long-term
potential of ICT therapy in MDS.
There is accumulating evidence to suggest that iron overload
is associated with increased treatment-related mortality after allo-
geneic stem cell transplantation (allo-SCT) in MDS  [57]. In addition,
progressive iron overload in the heart can result in cardiac com-
plications. Magnetic resonance imaging (MRI) T2-weighted (T2*)
assessment can provide an estimate of cardiac iron deposition,
allowing initiation of ICT before cardiac symptoms develop. Low
cardiac T2* MRI  values (<20 ms)  predicted a high risk of develop-
ing heart failure in a study of 75 regularly transfused MDS  patients
[58]. Based on these ﬁndings, both lower-risk patients who  may  be
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onsidered for allo-SCT and those with low heart T2* values may
e candidates for ICT.
. Other treatment options for lower-risk non-del(5q) MDS
.1. Immunosuppressive therapy (IST)
IST is a treatment option for a select group of lower-risk non-
el(5q) patients. Those most likely to respond are aged <60 years
ith <5% blasts, or those with hypocellular bone marrow, human
eukocyte antigen DR15 class II phenotype, presence of a paroxys-
al  nocturnal hemoglobinuria clone, trisomy 8, or STAT-3-mutant
ytotoxic T-cell clones [18,19]. Studies of antithymocyte globulin
ATG), cyclosporin A (CSA), or a combination have reported hema-
ologic improvement in approximately 20–60% of selected patients
ith MDS  [59–65], although patient selection criteria varied con-
iderably between studies, particularly in terms of the MDS  subtype
nd the cytogenetic proﬁle of patients. Results of a multicenter,
andomized Phase 3 study conﬁrmed the potential beneﬁts of IST
een in single-arm studies for patients with MDS  [64]. In this study,
atients were randomized to a combination of horse ATG and CSA
ersus best supportive care. At 6 months, the proportion of patients
ho achieved a hematologic response was signiﬁcantly higher in
he ATG plus CSA treatment group (29%) than in the best support-
ve care group (9%; p = 0.0156). Responses to ATG were durable in
he majority of patients (median: 16.4 months). Despite higher
esponse rates, no signiﬁcant effect on transformation-free sur-
ival was observed. Adverse events, including hematologic toxicity
nd associated severe adverse events, such as hemorrhage and
nfections, have been reported with IST. The monoclonal antibody
lemtuzumab, which targets CD52 on lymphocytes, has also pro-
uced response rates of up to 68% in relatively small studies of
ighly selected patients with lower-risk MDS  [66–68]. While clini-
al trials are ongoing in the USA, alemtuzumab is no longer available
or use in lower-risk MDS  in Europe.
.2. Hypomethylating agents (HMAs)
HMAs are a well-established treatment option for higher-risk
DS  and AML  [69–72]. Azacitidine has been shown to prolong sur-
ival and improve quality of life in higher-risk MDS  patients [73].
MAs may  be an option for lower-risk non-del(5q) patients who
re unresponsive or refractory to ESAs and have a low probabil-
ty of responding to IST [18]. HMAs are approved in the USA and
apan for treatment of lower-risk MDS, but are currently not an
pproved treatment in the EU. Data suggest that the HMAs azaciti-
ine and decitabine are effective in lower-risk non-del(5q) patients,
roducing RBC-TI rates of 10–60% and hematologic improve-
ent in 25–55% of patients [74–78]. However, response data are
ery heterogeneous, and prospective data are limited. In the only
rospective study to date, 20% of ESA-refractory patients achieved
BC-TI, although for the majority of these (4 of 6), the duration of
esponse was less than 6 months [79].
Oral administration of azacitidine may  allow for extended dos-
ng schedules. Phase 1 studies with oral azacitidine (CC-486) have
hown biological activity and tolerability in patients with MDS
nd AML. In a recent Phase 1/2 trial in which lower-risk patients
eceived oral azacitidine 300 mg  once daily in extended treatment
chedules, overall response (i.e., complete or partial remission,
BC or platelet TI, or hematologic improvement [International
orking Group (IWG) 2006 response criteria]) was attained by
6% of patients receiving 14-day dosing and 41% receiving 21-day
osing [80]. Extended dosing schedules of oral azacitidine are cur-
ently under investigation as ﬁrst-line therapy in patients withsearch 52 (2017) 50–57 53
lower-risk MDS  and thrombocytopenia (ClinicalTrials.gov Identi-
ﬁer: NCT01566695).
4.3. Allogeneic stem cell transplantation (allo-SCT)
Allo-SCT is typically reserved for medically ﬁt higher-risk MDS
patients [18]. It may  be considered an option for selected lower-risk
patients, such as those aged <60–70 years with IPSS Intermediate-
1-risk MDS, poor-risk cytogenetics, or persistent blast elevation,
if alternative therapeutic options, including growth factors, IST,
and HMAs, are ineffective [19,81]. In a decision analysis, Cutler
et al. [82] found that delaying allo-SCT maximized OS in lower-
risk patients, especially in those aged <40 years. Outcomes were
also improved when allo-SCT was done before progression to AML.
Using a continuous-time multistate Markov model, Alessandrino
et al. [83] recently compared allo-SCT with best supportive care in
patients aged ≤65 years. In this analysis, estimated life expectancy
increased when transplantation was  delayed from the initial stages
of MDS  until progression to IPSS Intermediate-1 risk, and decreased
in higher-risk patients [83]. These data suggest that an optimal
therapeutic window for allo-SCT exists between worsening of the
disease and leukemic transformation [81–83].
5. Recent advances
5.1. Treatment of anemia in lower-risk MDS
There is an unmet therapeutic need in lower-risk non-del(5q)
MDS  patients who  are ineligible for or unresponsive to ESAs. Several
therapeutic approaches are currently being explored in an effort to
reduce RBC-TD in this setting.
5.2. Lenalidomide
Lenalidomide is approved by the US Food and Drug Administra-
tion (FDA) for the treatment of patients who  have TD anemia due
to IPSS lower-risk MDS  with del(5q) with or without additional
cytogenetic abnormalities [84]; in the EU, its use is restricted to
RBC-TD IPSS Low- or Intermediate-1-risk MDS  with isolated del(5q)
[85]. In non-del(5q) MDS, lenalidomide has been shown to induce
durable RBC-TI in 26% of patients [86]. Use of lenalidomide in non-
del(5q) patients with anemia who  are ineligible for or refractory to
ESAs was recently assessed in a Phase 3 placebo-controlled study
[87]. Overall, 27% of patients treated with lenalidomide achieved
RBC-TI ≥ 8 weeks compared with 2.5% of patients treated with
placebo (P < 0.001). The median duration of RBC-TI with lenalido-
mide was  30.9 weeks (95% conﬁdence interval, 20.7–59.1). Low
baseline serum EPO level predicted response to lenalidomide [88],
and response to lenalidomide was  associated with improved HRQoL
[89]. The adverse event proﬁle of lenalidomide in non-del(5q)
patients was  consistent with data in del(5q) MDS patients [84,87],
with the principal adverse events being grade 3–4 neutropenia and
thrombocytopenia, while the frequency of these events was lower
in non-del(5q) patients (49.3% vs. 73.7% for neutropenia and 37.3%
vs. 64.2% for thrombocytopenia) [90].
There is evidence to suggest that the efﬁcacy of lenalidomide
may  be improved in this setting by combining it with ESAs [91–94].
In a Phase 3 trial evaluating lenalidomide with or without rhEPO
in 131 RBC-TD patients with lower-risk non-del(5q) MDS  refrac-
tory to ESAs, combination therapy induced erythroid response in
approximately 40% of patients (vs. 23% with lenalidomide alone;
p = 0.044) and RBC-TI in 24% of patients (vs. 14% with lenalidomide
alone; p = 0.13) [93]. The median duration of erythroid response
was 18.1 months with lenalidomide and 15.1 months with the
combination of lenalidomide and rhEPO. A Phase 3 trial by the
ECOG-ACRIN Cancer Research Group evaluating lenalidomide alone
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IST or novel 
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LEN or HMA †) 
All o-
cli nical trial
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† Poor probability to respond to IST; NCC N recommend aon only [18 ].
‡ Select paents only [18 ,19] .
Fail ure
Fail ure
Fig. 1. Proposed therapeutic algorithm for lower-risk non-del(5q) MDS. Allo-SCT,
allogeneic stem cell transplantation; EPO, erythropoietin; ESA, erythropoiesis-
stimulating agent; G-CSF, granulocyte colony-stimulating factor; HMA, hypomethy-
lating agent;.
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r in combination with EPO in lower-risk MDS  patients who are
ither unresponsive or have a low probability to respond to EPO
ecently completed accrual.
Lenalidomide and azacitidine are used as single agents in
atients with lower-risk non-del(5q) MDS  after failure of treat-
ent with ESAs [95]. In a retrospective analysis of non-del(5q) MDS
atients failing ESAs, rates of erythroid hematologic improvement
ere signiﬁcantly higher in patients who received lenalidomide as
rst-line therapy compared with those who received lenalidomide
s second-line therapy following azacitidine treatment (38% vs.
2%; p = 0.04) [95]. Although these data require validation in larger
ohorts, this ﬁnding suggests that lenalidomide should be consid-
red before azacitidine after ESA treatment failure in lower-risk
on-del(5q) MDS  patients.
. Future directions
Efforts to optimize the beneﬁts of therapies currently avail-
ble to patients with lower-risk non-del(5q) MDS  remain a priority
Fig. 1). This includes improved methods for proﬁling patients,
redicting response, and integrating the results of molecular stud-
es into clinical practice [96–98]. Combining available agents with
ifferent modes of action (e.g., ESAs and HMAs) may  improve out-
omes and should continue to be evaluated. Evaluation of novel
gents that address biologically relevant targets is also underway.
.1. Activin receptor type II ligand traps
The activin receptor type II ligand traps, luspatercept and
otatercept, were well tolerated and exhibited promising activity
n Phase 2 trials of patients with lower-risk MDS  who  were ineligi-
le for or refractory or unresponsive to ESAs [99,100]. Encouraging
esponse rates were observed with luspatercept in ring sideroblast-
ositive/SF3B1 mutation-positive patients, although the number of
on-sideroblastic patients in this study was small [100,101]. Ansearch 52 (2017) 50–57
open-label extension study to assess long-term safety and tolerabil-
ity of luspatercept among patients previously enrolled in this Phase
2 trial is ongoing. Luspatercept is being investigated in a Phase 3
study for treatment of anemia in patients with IPSS-R Very Low-,
Low-, or Intermediate-risk MDS  and ring sideroblasts who require
regular RBC transfusions.
6.2. Small-molecule inhibitors
A number of small-molecule inhibitors of cell signaling have
shown promising activity in lower-risk MDS. Rigosertib, a PI3K/PLK
pathway inhibitor, has shown clinical efﬁcacy in Phase 1 trials with
MDS  patients (of whom 62% had IPSS lower-risk MDS); studies are
ongoing [102]. SCIO-469, a selective inhibitor of p38- MAPK, was
well tolerated in EPO-refractory lower-risk MDS  patients; however,
effects were modest, producing an erythroid response in only 18%
of patients [103]. Similar results were obtained in an open-label,
randomized Phase 1 study of the dual p38 MAPK/Tie2 inhibitor
ARRY-614 in lower-risk MDS  patients [104].
6.3. Treatment of thrombocytopenia
Profound thrombocytopenia is an uncommon event in lower-
risk MDS. Platelet transfusions are the only available treatment
option other than azanucleosides, and effective treatment of
thrombocytopenia remains an unmet medical need.
Thrombopoietin mimetic agents, such as romiplostim and
eltrombopag, are promising in their ability to decrease bleeding
events and the need for platelet transfusions [105–109]. The need
for dose reductions of some disease-modifying agents that cause
thrombocytopenia, such as azacitidine, decitabine, and lenalido-
mide [105,110], may  also be avoided. The beneﬁts of romiplostim
and eltrombopag therapy have been evaluated in several studies.
The largest study randomized 250 lower-risk MDS  patients with
thrombocytopenia to receive romiplostim or placebo [108]. Com-
pared with placebo, patients in the romiplostim group showed
a reduced incidence of bleeding events (relative risk: 0.92) and
platelet transfusions (relative risk: 0.77). Platelet response rates
were also higher in the romiplostim treatment group (odds ratio:
15.6). Based on the transient increase in peripheral blast cell counts
associated with romiplostim treatment, it has been suggested that
romiplostim treatment may  confer an increased risk of progres-
sion to AML. Although results with romiplostim are not consistent
across trials [106,108–110], based on updated results from the only
prospective randomized Phase 2 trial, short-term treatment with
romiplostim did not appear to increase the risk of AML  progression
[109].
Similar to romiplostim, eltrombopag is also being evaluated for
treatment of thrombocytopenia in patients with MDS. Preliminary
results from a randomized Phase 2 study of eltrombopag indi-
cate signiﬁcant improvements in platelet counts in IPSS lower-risk
MDS patients with severe thrombocytopenia [111]. At the time of
the interim analysis, 23 of 46 patients (50%) in the eltrombopag
group achieved a platelet response compared with 2 of 24 patients
(8%) in the placebo group (p = 0.001). Although a longer follow-up
period is required to evaluate the impact on survival, responding
patients exhibited signiﬁcant improvements in fatigue and showed
no sign of an increased risk of leukemic transformation. A recent
randomized trial of eltrombopag in combination with azacitidine
in higher-risk MDS  has been prematurely stopped due to lack of
beneﬁt (ClinicalTrials.gov Identiﬁer: NCT02158936).
Extended dosing of oral azacitidine 300 mg/day on days 1–21 of
each 28-day cycle is being evaluated for treatment of TD lower-risk
MDS  patients with thrombocytopenia and anemia.
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. Conclusions
In summary, the current goal of therapy for lower-risk MDS  is to
educe RBC transfusion requirement to avoid the negative conse-
uences of long-term, chronic transfusions. Whereas ESAs are the
ainstay of treatment for patients without del(5q), few available
reatment options have been shown to provide a durable impact
n RBC transfusion requirement after ESA failure. Recent insights
nto the biology of MDS  will lead to a better understanding of the
eterogeneity that exists among MDS  patients and an apprecia-
ion of the need for a more individualized approach to therapy.
urrent research is exploring promising agents and combinations
ith the aim of identifying the best options to allow a more tai-
ored approach to patient management. The search continues for
reatment options that can alter the course of the disease.
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